Pentwater Capital Management LP reduced its stake in PAREXEL International Co. (NASDAQ:PRXL) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 198,000 shares of the medical research company’s stock after selling 2,000 shares during the period. Pentwater Capital Management LP owned approximately 0.39% of PAREXEL International worth $17,440,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. World Asset Management Inc grew its stake in shares of PAREXEL International by 0.3% during the second quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 9 shares in the last quarter. 1st Global Advisors Inc. grew its stake in shares of PAREXEL International by 0.4% during the second quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock valued at $469,000 after acquiring an additional 21 shares in the last quarter. Amalgamated Bank grew its stake in shares of PAREXEL International by 0.6% during the second quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock valued at $631,000 after acquiring an additional 42 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of PAREXEL International by 4.5% during the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 73 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of PAREXEL International by 10.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock valued at $173,000 after acquiring an additional 180 shares in the last quarter. Hedge funds and other institutional investors own 87.45% of the company’s stock.
Separately, Zacks Investment Research downgraded PAREXEL International from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. PAREXEL International has an average rating of “Hold” and an average price target of $80.76.
PAREXEL International Co. (PRXL) opened at $88.08 on Monday. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 1.01. PAREXEL International Co. has a twelve month low of $51.16 and a twelve month high of $88.10.
WARNING: This piece of content was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thestockobserver.com/2017/12/11/parexel-international-co-prxl-shares-sold-by-pentwater-capital-management-lp.html.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.